^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EP300 overexpression

    i
    Other names: EP300, E1A binding protein p300, p300, KAT3B, RSTS2
    Entrez ID:
    2033
    Related biomarkers:
    Mutation
    Others
    2ms
    Establishment of BCL-2 Inhibitors-Resistant B-cell Acute Lymphoblastic Leukemia Cell Lines and Study on Their Resistance Mechanisms (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    Drug-resistant B-ALL cell lines could be successfully established by exposing RS4;11 cell line to the ascending concentration of BCL-2 inhibitors, and the drug resistance mechanism may be related to the overexpression of EP300.
    Preclinical • Journal • IO biomarker
    |
    EP300 (E1A binding protein p300)
    |
    BCL2 expression • EP300 overexpression
    |
    Venclexta (venetoclax) • navitoclax (ABT 263)
    1year
    NDUFA8 is transcriptionally regulated by EP300/H3K27ac and promotes mitochondrial respiration to support proliferation and inhibit apoptosis in cervical cancer. (PubMed, Biochem Biophys Res Commun)
    By promoting mitochondrial respiration, NDUFA8 contributes to cervical cancer cell proliferation and apoptosis. These findings provide novel insights into NDUFA8 as a therapeutic target in cervical cancer.
    Journal
    |
    EP300 (E1A binding protein p300)
    |
    EP300 overexpression